OBJECTIVES: This study was undertaken to evaluate the ability of myocardial contrast echocardiography (MCE) to guide the targeted delivery of @entity1068 during nonsurgical septal reduction therapy (NSRT) and to assess the relation between the MCE risk area and @entity1188 size determined by enzymatic and radionuclide methods. BACKGROUND: NSRT with intracoronary @entity1068 is a new promising treatment for @entity1 with @entity1121 ( @entity1121 ). Proper localization and quantification of the septal @entity1188 before @entity1068 injection are highly desirable. MCE can provide accurate delineation of the vascular territory of the coronary arteries. METHODS: Twenty-nine @entity1 with @entity1121 and maximal medical therapy underwent NSRT. The left ventricular outflow tract (LVOT) gradient by Doppler echocardiography at baseline was 53 +/- 16 mm Hg (mean +/- SD). Before NSRT, MCE was performed in all @entity1 with intracoronary sonicated albumin (Albunex). Diluted sonicated albumin (Albunex) was selectively injected into the septal perforator arteries during simultaneous transthoracic imaging. Immediately after MCE, @entity1068 was injected into the same vessel. Plasma total @entity908 kinase (CK), total CK-MB fraction and CK-MB fraction subforms were measured at baseline and serially for 36 h. RESULTS: LVOT gradient decreased to 12 +/- 6 mm Hg (p < 0.001) after NSRT. Accurate mapping of the vascular beds of the septal perforators was successfully attained in all @entity1 by MCE. Furthermore, the MCE risk area correlated well with peak CK (r = 0.79, p < 0.001). Six weeks after NSRT, 23 @entity1 underwent myocardial perfusion studies performed with single-photon emission computed tomography (SPECT). Mean SPECT septal perfusion defect size involved 9.5 +/- 6% of the left ventricle and correlated well with MCE area (r = 0.7), with no statistically significant difference between the risk area estimated by MCE and that by SPECT. CONCLUSIONS: Estimation of the size of the septal vascular territory with MCE is accurate, safe and feasible in essentially all @entity1 during NSRT. MCE can delineate the perfusion bed of the septal perforators and can predict the @entity1188 size that follows @entity1068 injection.

Role of myocardial contrast echocardiography during nonsurgical septal reduction therapy for XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity908 :: ('MESH:D003401', 'Chemical') :: ['creatine'] @entity1188 :: ('MESH:D007238', 'Disease') :: ['infarct'] @entity1121 :: ('MESH:D002312', 'Disease') :: ['HOCM', 'hypertrophic obstructive cardiomyopathy'] @entity1068 :: ('MESH:D000431', 'Chemical') :: ['ethanol']
@entity1121 :: (MESH:D002312,Disease) :: ['hypertrophic obstructive cardiomyopathy']
